메뉴 건너뛰기




Volumn 123, Issue 22, 2014, Pages 3390-3397

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

(19)  Brown, Jennifer R a   Byrd, John C b   Coutre, Steven E c   Benson, Don M b   Flinn, Ian W d   Wagner Johnston, Nina D e   Spurgeon, Stephen E f   Kahl, Brad S g   Bello, Celeste h   Webb, Heather K i   Johnson, Dave M i   Peterman, Sissy i   Li, Daniel i   Jahn, Thomas M i   Lannutti, Brian J i   Ulrich, Roger G i   Yu, Albert S i   Miller, Langdon L i   Furman, Richard R j  


Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ANTIBIOTIC AGENT; ASPARTATE AMINOTRANSFERASE; CD16 ANTIGEN; CD56 ANTIGEN; GAMMA GLUTAMYLTRANSFERASE; GLUCOSE; HEMOGLOBIN; IDELALISIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN P110; PROTEIN P110 DELTA; PROTEIN P53; STEROID; UNCLASSIFIED DRUG;

EID: 84901712964     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-11-535047     Document Type: Article
Times cited : (564)

References (35)
  • 1
    • 84865082196 scopus 로고    scopus 로고
    • Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia
    • Cheson BD, Byrd JC, Rai KR, et al. Novel targeted agents and the need to refine clinical end points in chronic lymphocytic leukemia. J Clin Oncol. 2012;30(23):2820-2822.
    • (2012) J Clin Oncol , vol.30 , Issue.23 , pp. 2820-2822
    • Cheson, B.D.1    Byrd, J.C.2    Rai, K.R.3
  • 2
    • 84879779196 scopus 로고    scopus 로고
    • Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes [letter]
    • Hallek M, Cheson BD, Catovsky D, et al. Response assessment in chronic lymphocytic leukemia treated with novel agents causing an increase of peripheral blood lymphocytes [letter]. Blood. 2012;119(23): 5348.
    • (2012) Blood , vol.119 , Issue.23 , pp. 5348
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 3
    • 40749132494 scopus 로고    scopus 로고
    • Chronic lymphocytic leukaemia
    • DOI 10.1016/S0140-6736(08)60456-0, PII S0140673608604560
    • Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet. 2008;371(9617):1017-1029. (Pubitemid 351389535)
    • (2008) The Lancet , vol.371 , Issue.9617 , pp. 1017-1029
    • Dighiero, G.1    Hamblin, T.2
  • 4
    • 77957664665 scopus 로고    scopus 로고
    • Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial
    • Hallek M, Fischer K, Fingerle-Rowson G, et al.; International Group of Investigators; German Chronic Lymphocytic Leukaemia Study Group. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164-1174.
    • (2010) Lancet , vol.376 , Issue.9747 , pp. 1164-1174
    • Hallek, M.1    Fischer, K.2    Fingerle-Rowson, G.3
  • 5
    • 79954435811 scopus 로고    scopus 로고
    • Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: Long-term follow-up of CALGB study 9712
    • Woyach JA, Ruppert AS, Heerema NA, et al. Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712. J Clin Oncol. 2011;29(10):1349-1355.
    • (2011) J Clin Oncol , vol.29 , Issue.10 , pp. 1349-1355
    • Woyach, J.A.1    Ruppert, A.S.2    Heerema, N.A.3
  • 6
    • 80053366228 scopus 로고    scopus 로고
    • Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: Long-term follow-up of US Intergroup Study E2997
    • Smith MR, Neuberg D, Flinn IW, et al. Incidence of therapy-related myeloid neoplasia after initial therapy for chronic lymphocytic leukemia with fludarabine-cyclophosphamide versus fludarabine: long-term follow-up of US Intergroup Study E2997. Blood. 2011;118(13):3525-3527.
    • (2011) Blood , vol.118 , Issue.13 , pp. 3525-3527
    • Smith, M.R.1    Neuberg, D.2    Flinn, I.W.3
  • 7
    • 33746257209 scopus 로고    scopus 로고
    • The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
    • DOI 10.1038/nrg1879, PII NRG1879
    • Engelman JA, Luo J, Cantley LC. The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 2006; 7(8):606-619. (Pubitemid 44100518)
    • (2006) Nature Reviews Genetics , vol.7 , Issue.8 , pp. 606-619
    • Engelman, J.A.1    Luo, J.2    Cantley, L.C.3
  • 8
    • 0038549067 scopus 로고    scopus 로고
    • PI3K in lymphocyte development, differentiation and activation
    • Okkenhaug K, Vanhaesebroeck B. PI3K in lymphocyte development, differentiation and activation. Nat Rev Immunol. 2003;3(4):317-330. (Pubitemid 37328684)
    • (2003) Nature Reviews Immunology , vol.3 , Issue.4 , pp. 317-330
    • Okkenhaug, K.1    Vanhaesebroeck, B.2
  • 9
    • 77957201023 scopus 로고    scopus 로고
    • Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals
    • Herman SE, Gordon AL, Wagner AJ, et al. Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals. Blood. 2010; 116(12):2078-2088.
    • (2010) Blood , vol.116 , Issue.12 , pp. 2078-2088
    • Herman, S.E.1    Gordon, A.L.2    Wagner, A.J.3
  • 10
    • 78751553221 scopus 로고    scopus 로고
    • CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability
    • Lannutti BJ, Meadows SA, Herman SE, et al. CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood. 2011; 117(2):591-594.
    • (2011) Blood , vol.117 , Issue.2 , pp. 591-594
    • Lannutti, B.J.1    Meadows, S.A.2    Herman, S.E.3
  • 12
    • 80053345977 scopus 로고    scopus 로고
    • The phosphoinositide 39-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia
    • Hoellenriegel J, Meadows SA, Sivina M, et al. The phosphoinositide 39-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. Blood. 2011;118(13):3603- 3612.
    • (2011) Blood , vol.118 , Issue.13 , pp. 3603-3612
    • Hoellenriegel, J.1    Meadows, S.A.2    Sivina, M.3
  • 13
    • 84868013848 scopus 로고    scopus 로고
    • Decreased mitochondrial apoptotic priming underlies stromamediated treatment resistance in chronic lymphocytic leukemia
    • Davids MS, Deng J, Wiestner A, et al. Decreased mitochondrial apoptotic priming underlies stromamediated treatment resistance in chronic lymphocytic leukemia. Blood. 2012;12017 3501-3509.
    • (2012) Blood , vol.120 , Issue.17 , pp. 3501-3509
    • Davids, M.S.1    Deng, J.2    Wiestner, A.3
  • 14
    • 84859792782 scopus 로고    scopus 로고
    • Clinical pharmacokinetics of CAL-101, a p110{delta} isoform-selective PI3K inhibitor, following singleand multiple-dose administration in healthy volunteers and patients with hematological malignancies
    • Webb HK, Chen H, Yu AS, et al. Clinical pharmacokinetics of CAL-101, a p110{delta} isoform-selective PI3K inhibitor, following singleand multiple-dose administration in healthy volunteers and patients with hematological malignancies. ASH Annual Meeting Abstracts. 2010;116(21):1774.
    • (2010) ASH Annual Meeting Abstracts , vol.116 , Issue.21 , pp. 1774
    • Webb, H.K.1    Chen, H.2    Yu, A.S.3
  • 15
    • 45149100665 scopus 로고    scopus 로고
    • International workshop on chronic lymphocytic leukemia guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the international workshop on chronic lymphocytic leukemia updating the national cancer institute-working group 1996 guidelines
    • Hallek M, Cheson BD, Catovsky D, et al.; International Workshop on Chronic Lymphocytic Leukemia. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood. 2008;111(12):5446-5456.
    • (2008) Blood , vol.111 , Issue.12 , pp. 5446-5456
    • Hallek, M.1    Cheson, B.D.2    Catovsky, D.3
  • 16
    • 77949881462 scopus 로고    scopus 로고
    • The PI3K pathway as drug target in human cancer
    • Courtney KD, Corcoran RB, Engelman JA. The PI3K pathway as drug target in human cancer. J Clin Oncol. 2010;28(6):1075-1083.
    • (2010) J Clin Oncol , vol.28 , Issue.6 , pp. 1075-1083
    • Courtney, K.D.1    Corcoran, R.B.2    Engelman, J.A.3
  • 17
    • 84865074467 scopus 로고    scopus 로고
    • Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway
    • Busaidy NL, Farooki A, Dowlati A, et al. Management of metabolic effects associated with anticancer agents targeting the PI3K-Akt-mTOR pathway. J Clin Oncol. 2012;30(23):2919-2928.
    • (2012) J Clin Oncol , vol.30 , Issue.23 , pp. 2919-2928
    • Busaidy, N.L.1    Farooki, A.2    Dowlati, A.3
  • 18
    • 0036534380 scopus 로고    scopus 로고
    • Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: Implications for clinical trials in this patient population
    • DOI 10.1002/cncr.10437
    • Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer. 2002;94(7):2033-2039. (Pubitemid 34270057)
    • (2002) Cancer , vol.94 , Issue.7 , pp. 2033-2039
    • Perkins, J.G.1    Flynn, J.M.2    Howard, R.S.3    Byrd, J.C.4
  • 19
    • 84886313545 scopus 로고    scopus 로고
    • Final results of a phase i study of idelalisib, a selective inhibitor of PI3Kd, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
    • Benson DM, Kahl BS, Furman RR, et al. Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kd, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL). J Clin Oncol. 2013;31(suppl):8526.
    • (2013) J Clin Oncol , vol.31 , Issue.SUPPL. , pp. 8526
    • Benson, D.M.1    Kahl, B.S.2    Furman, R.R.3
  • 20
    • 80055021878 scopus 로고    scopus 로고
    • Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: In vivo evidence of immune activation and antitumour response
    • Chanan-Khan AA, Chitta K, Ersing N, et al. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011; 155(4):457-467.
    • (2011) Br J Haematol , vol.155 , Issue.4 , pp. 457-467
    • Chanan-Khan, A.A.1    Chitta, K.2    Ersing, N.3
  • 21
    • 4043082729 scopus 로고    scopus 로고
    • Cuttin edge: Differential roles for phosphoinositide 3-kinases, p110γ and p110δ, lymphocyte chemotaxis and homing
    • Reif K, Okkenhaug K, Sasaki T, Penninger JM, Vanhaesebroeck B, Cyster JG. Cutting edge: differential roles for phosphoinositide 3-kinases, p110gamma and p110delta, in lymphocyte chemotaxis and homing. J Immunol. 2004;173(4): 2236-2240. (Pubitemid 39063077)
    • (2004) Journal of Immunology , vol.173 , Issue.4 , pp. 2236-2240
    • Reif, K.1    Okkenhaug, K.2    Sasaki, T.3    Penninger, J.M.4    Vanhaesebroeck, B.5    Cyster, J.G.6
  • 22
    • 77951002653 scopus 로고    scopus 로고
    • Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia
    • Friedberg JW, Sharman J, Sweetenham J, et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. Blood. 2010;115(13):2578-2585.
    • (2010) Blood , vol.115 , Issue.13 , pp. 2578-2585
    • Friedberg, J.W.1    Sharman, J.2    Sweetenham, J.3
  • 23
    • 77951450222 scopus 로고    scopus 로고
    • The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation
    • Zent CS, LaPlant BR, Johnston PB, et al. The treatment of recurrent/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL) with everolimus results in clinical responses and mobilization of CLL cells into the circulation. Cancer. 2010;116(9):2201-2207.
    • (2010) Cancer , vol.116 , Issue.9 , pp. 2201-2207
    • Zent, C.S.1    Laplant, B.R.2    Johnston, P.B.3
  • 24
    • 84871806385 scopus 로고    scopus 로고
    • Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies
    • Advani RH, Buggy JJ, Sharman JP, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/ refractory B-cell malignancies. J Clin Oncol. 2013; 31(1):88-94.
    • (2013) J Clin Oncol , vol.31 , Issue.1 , pp. 88-94
    • Advani, R.H.1    Buggy, J.J.2    Sharman, J.P.3
  • 25
    • 84879748062 scopus 로고    scopus 로고
    • Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia
    • Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
    • (2013) N Engl J Med , vol.369 , Issue.1 , pp. 32-42
    • Byrd, J.C.1    Furman, R.R.2    Coutre, S.E.3
  • 26
    • 84876477884 scopus 로고    scopus 로고
    • Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling
    • Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. Blood. 2013;121(9): 1501-1509.
    • (2013) Blood , vol.121 , Issue.9 , pp. 1501-1509
    • Burger, J.A.1    Montserrat, E.2
  • 28
    • 0035469851 scopus 로고    scopus 로고
    • Rituximab therapy of patients with B-cell chronic lymphocytic leukemia
    • Huhn D, von Schilling C, Wilhelm M, et al.; German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood. 2001;98(5): 1326-1331.
    • (2001) Blood , vol.98 , Issue.5 , pp. 1326-1331
    • Huhn, D.1    Von Schilling, C.2    Wilhelm, M.3
  • 30
    • 0036757311 scopus 로고    scopus 로고
    • Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: Results from a nordic multicentre study
    • DOI 10.1034/j.1600-0609.2002.02786.x
    • Itälä M, Geisler CH, Kimby E, et al. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol. 2002; 69(3):129-134. (Pubitemid 35335149)
    • (2002) European Journal of Haematology , vol.69 , Issue.3 , pp. 129-134
    • Itala, M.1    Geisler, Ch.2    Kimby, E.3    Juvonen, E.4    Tjonnfjord, G.5    Karlsson, K.6    Remes, K.7
  • 32
    • 69849107362 scopus 로고    scopus 로고
    • Subcutaneous alemtuzumab in fludarabinerefractory chronic lymphocytic leukemia: Clinical results and prognostic marker analyses from the cll2h study of the german chronic lymphocytic leukemia study group
    • Stilgenbauer S, Zenz T, Winkler D, et al.; German Chronic Lymphocytic Leukemia Study Group. Subcutaneous alemtuzumab in fludarabinerefractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group. J Clin Oncol. 2009; 27(24):3994-4001.
    • (2009) J Clin Oncol , vol.27 , Issue.24 , pp. 3994-4001
    • Stilgenbauer, S.1    Zenz, T.2    Winkler, D.3
  • 33
    • 77950502126 scopus 로고    scopus 로고
    • Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabinerefractory chronic lymphocytic leukemia
    • Wierda WG, Kipps TJ, Mayer J, et al.; Hx-CD20-406 Study Investigators. Ofatumumab as single-agent CD20 immunotherapy in fludarabinerefractory chronic lymphocytic leukemia. J Clin Oncol. 2010;28(10):1749-1755.
    • (2010) J Clin Oncol , vol.28 , Issue.10 , pp. 1749-1755
    • Wierda, W.G.1    Kipps, T.J.2    Mayer, J.3
  • 35
    • 45949100928 scopus 로고    scopus 로고
    • Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia
    • Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood. 2008; 111(11):5291-5297.
    • (2008) Blood , vol.111 , Issue.11 , pp. 5291-5297
    • Ferrajoli, A.1    Lee, B.N.2    Schlette, E.J.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.